Ethinyl Estradiol and Desogestrel
Brand names: Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol · Active ingredient: Desogestrel, Ethinyl Estradiol
In short: Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective.
What is Ethinyl Estradiol and Desogestrel used for?
Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Oral contraceptives are highly effective.
Table IIlists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.
% of Women Experiencing an Unintended Pregnancy within the First Year of Use | % of Women
Continuing Use at
One Year
a
Method
(1) | Typical Use
b
(2) | Perfect Use
c
(3)
(4)
Chance
d | 85 | 85
Spermicides
e | 26 | 6 | 40
Periodic Abstinence | 25 | 63
Calendar | 9
Ovulation Method | 3
Sympto-Thermal
f | 2
Post-Ovulation | 1
Withdrawal | 19 | 4
Cap
g
Parous Women | 40 | 26 | 42
Nulliparous Women | 20 | 9 | 56
Sponge
Parous Women | 40 | 20 | 42
Nulliparous Women | 20 | 9 | 56
Diaphragm
g | 20 | 6 | 56
Condom
h
Female (Reality) | 21 | 5 | 56
Male | 14 | 3 | 61
Pill | 5 | 71
Progestin Only | 0.5
Combined | 0.1
IUD
Progesterone T | 2 | 1.5 | 81
Copper T 380A | 0.8 | 0.6 | 78
LNg 20 | 0.1 | 0.1 | 81
Depo-Provera | 0.3 | 0.3 | 70
Norplant and Norplant-2 | 0.05 | 0.05 | 88
Female Sterilization | 0.5 | 0.5 | 100
Male Sterilization | 0.15 | 0.10 | 100
Adapted from Hatcher et al., 1998, ref #1. …
âš Boxed warning (FDA's strongest warning)
The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes.
Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.
The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with formulations of higher doses of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with formulations of lower doses of both estrogens and progestogens remains to be determined.
Throughout this labeling, epidemiologic studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among non-users. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and non-users. …
Ethinyl Estradiol and Desogestrel dosage
To achieve maximum contraceptive effectiveness,Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP must be taken exactly as directed and at intervals not exceeding 24 hours. Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP may be initiated using either a Sunday start or a Day 1 start.
NOTE: Each cycle pack dispenser is preprinted with the days of the week, starting with Sunday, to facilitate a Sunday start regimen. Six different “day label strips” are provided with each cycle pack dispenser in order to accommodate a Day 1 start regimen. In this case, the patient should place the self-adhesive “day label strip” that corresponds to her starting day over the preprinted days.
IMPORTANT: The possibility of ovulation and conception prior to initiation of use of Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP should be considered.
The use of Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP for contraception may be initiated 4 weeks postpartum in women who elect not to breastfeed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see
CONTRAINDICATIONSand
WARNINGSconcerning thromboembolic disease. See also
PRECAUTIONSfor Nursing mothers).
If the patient starts on Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a white tablet has been taken daily for 7 days.
When initiating a Sunday start regimen, another method of contraception should be used until after the first 7 consecutive days of administration.
Using a Sunday start, tablets are taken daily without interruption as follows: The first white tablet should be taken on the first Sunday after menstruation begins (if menstruation begins on Sunday, the first white tablet is taken on that day). One white tablet is taken daily for 21 days, followed by 1 light-green (inert) tablet daily for 2 days and 1 yellow (active) tablet daily for 5 days. For all subsequent cycles, the patient then begins a new 28 tablet regimen on the next day (Sunday) after taking the last yellow tablet. [If switching from a Sunday start oral contraceptive, the first Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP should be taken on the second Sunday after the last tablet of a 21 day regimen or should be taken on the first Sunday after the last inactive tablet of a 28 day regimen.]
If a patient misses 1 white tablet, she should take the missed tablet as soon as she remembers. …
How to take Ethinyl Estradiol and Desogestrel — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (PATIENT PACKAGE INSERT BRIEF SUMMARY and DETAILED PATIENT PACKAGE INSERT).
Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs (
seeBOXED WARNING and CONTRAINDICATIONS).
Counsel patients that the increased risk of venous thromboembolism compared to nonusers of CHCs is greatest after initially starting a CHC or restarting (following a 4-week or greater interruption in intake) the same or a different CHC (
seeWARNINGS).
Counsel patients that this product does not protect against HIV-infection (AIDS) and other sexually transmitted infections.
Counsel patients to take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event pills are missed (
seeDOSAGE AND ADMINISTRATION).
Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs (
seePRECAUTIONS).
Counsel patients who are breastfeeding or who desire to breastfeed that COCs may reduce breast milk production. …
Warnings & precautions
Do not take this medicine if: Oral contraceptives should not be used in women who currently have the following conditions:
Thrombophlebitis or thromboembolic disorders
A past history of deep vein thrombophlebitis or thromboembolic disorders
Cerebral vascular or coronary artery disease
Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive
Undiagnosed abnormal genital bleeding
Cholestatic jaundice of pregnancy or jaundice with prior pill use
Hepatic adenomas or carcinomas
Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations .
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted infections.
It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen, and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care.
Women who are being treated for hyperlipidemias should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.
If jaundice develops in any woman receiving such drugs, the medication should be discontinued. …
Ethinyl Estradiol and Desogestrel side effects
An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives :
• Thrombophlebitis and venous thrombosis with or without embolism
• Arterial thromboembolism
• Pulmonary embolism
• Myocardial infarction
• Cerebral hemorrhage
• Cerebral thrombosis
• Hypertension
• Gallbladder disease
• Hepatic adenomas or benign liver tumors
Post Marketing Experience
Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2)(64 to 68).
Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 2)(64, 67, 69). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use.
Figure 2.RELEVANT STUDIES OF RISK OF BREAST CANCER WITH COMBINED ORAL CONTRACEPTIVES
RR = relative risk; OR = odds ratio; HR = hazard ratio. “ever COC” are females with current or past COC use; “never COC use” are females that never used COCs. …
About this medicine
Desogestrel and Ethinyl Estradiol Tablets, USP and Ethinyl Estradiol Tablets, USP provide an oral contraceptive regimen of 21 white to off white round tablets each containing 0.15 mg desogestrel (13-ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol), 0.02 mg ethinyl estradiol (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and inactive ingredients which include lactose monohydrate, pregelatinized starch (Maize starch), povidone K-30, vitamin E, stearic acid, colloidal anhydrous silica, purified talc, magnesium stearate, Hypromellose, Polyethylene glycol and followed by 2 inert light-green round tablets with the following inactive ingredients /lactose monohydrate, pregelatinized starch (Starch 1500), colloidal anhydrous silica, talc, magnesium stearate, hypromellose, triacetin, titanium dioxide, FD&C blue no. 1 aluminium lake, D&C yellow no. 10 aluminium lake, FD&C yellow no. 6 aluminium lake. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5a179f7b-a718-494f-8c97-ece34f356ca7. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone